LivaNova (NASDAQ:LIVN) Reaches New 1-Year High – Time to Buy?

LivaNova PLC (NASDAQ:LIVN) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $74.32 and last traded at $72.8950, with a volume of 801796 shares traded. The stock had previously closed at $72.23.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on LIVN shares. Mizuho boosted their target price on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Barclays boosted their target price on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Piper Sandler reaffirmed an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a report on Thursday, February 19th. Finally, Stifel Nicolaus set a $80.00 price objective on LivaNova in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $79.38.

LivaNova Price Performance

The stock has a market capitalization of $4.00 billion, a P/E ratio of 37.38 and a beta of 0.82. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. The stock has a 50-day simple moving average of $64.58 and a 200 day simple moving average of $63.13.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the company earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities analysts forecast that LivaNova PLC will post 3.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Hantz Financial Services Inc. raised its position in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after acquiring an additional 267 shares during the last quarter. State of Wyoming bought a new stake in shares of LivaNova during the 2nd quarter valued at $31,000. EverSource Wealth Advisors LLC raised its position in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after acquiring an additional 639 shares during the last quarter. Quarry LP bought a new stake in shares of LivaNova during the 3rd quarter valued at $36,000. Finally, UMB Bank n.a. raised its position in shares of LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after acquiring an additional 306 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.